Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516851 | 1.00 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL12595406 | 1.00 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL4412045 | 1.00 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL5981719 | 1.00 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL3516854 | 1.00 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL5981711 | 1.00 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL14429235 | 0.92 | HIF1A (0.51) | HIF1APNPLMNATP53HTT | |
| SCHEMBL26298184 | 0.89 | HIF1A (0.50) | HIF1APNPLMNATP53HTT | |
| SCHEMBL14580420 | 0.86 | HIF1A (0.45) | HIF1APNPLMNATP53HTT | |
| SCHEMBL19392034 | 0.83 | HIF1A (0.43) | HIF1APNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113913497-B | Method for detecting target nucleic acid by using single-stranded nucleic acid modified by base | 山东舜丰生物科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| WO-2023141604-A2 | METHODS OF MOLECULAR TAGGING FOR SINGLE-CELL ANALYSIS | MISSION BIO, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2022219409-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2022-10-20 | — | — | WO | claimed |
| CN-109863161-B | Labeled polynucleotides useful for nucleic acid sequencing | 豪夫迈·罗氏有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-4743590-A1 | MICROBIOME ANALYSIS | Readygo Diagnostics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4698678-A1 | A METHOD FOR PROFILING OF MUTATIONS VIA GAP FILLING ON RNA AND A KIT FOR USE IN A METHOD FOR PROFILING OF MUTATIONS | Voxlbio AB (SE) | 2026-02-25 | — | — | EP | disclosed |
| EP-4689159-A1 | METHOD AND KITS | Oxford Nanopore Technologies PLC (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025235935-A1 | METHODS OF SYNTHESIZING NUCLEIC ACID MOLECULES | TELESIS BIO INC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| CN-109863161-B | Labeled polynucleotides useful for nucleic acid sequencing | 豪夫迈·罗氏有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-107002151-B | Method of delivering an analyte to a transmembrane pore | 牛津纳米孔技术公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114107457-A | Method of delivering an analyte to a transmembrane pore | 牛津纳米孔技术公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| EP-3823976-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | Janssen Biotech, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112424212-A | Cyclic dinucleotides as STING agonists | 詹森生物科技公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020016782-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | HIF1A 1187/4885PNP 55/4885LMNA 793/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | HIF1A 2305/4885PNP 56/4885LMNA 1350/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | HIF1A 1415/4885PNP 319/4885LMNA 653/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | HIF1A 1162/4885PNP 487/4885LMNA 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.